COMPASS Pathways (CMPS) Stock Forecast & Price Target

Compare

2,074 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CMPS Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

COMPASS

Pathways

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CMPS Stock 12 Month Forecast

Average Price Target

$15.44

▲(227.12% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $15.44 with a high forecast of $40.00 and a low forecast of $6.00. The average price target represents a 227.12% change from the last price of $4.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","11":"$11","21":"$21","31":"$31","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,11,21,31,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.34,7.083076923076923,9.826153846153845,12.569230769230767,15.31230769230769,18.055384615384614,20.798461538461535,23.541538461538458,26.284615384615382,29.027692307692305,31.77076923076923,34.513846153846146,37.25692307692307,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.34,5.193846153846153,6.047692307692308,6.901538461538461,7.7553846153846155,8.60923076923077,9.463076923076922,10.316923076923077,11.170769230769231,12.024615384615384,12.878461538461538,13.732307692307693,14.586153846153845,{"y":15.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.34,4.467692307692308,4.595384615384615,4.723076923076923,4.850769230769231,4.978461538461539,5.1061538461538465,5.233846153846153,5.361538461538462,5.489230769230769,5.616923076923078,5.7446153846153845,5.872307692307692,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$15.44

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$45→$40

Buy

747.46%

Upside

Reiterated

08/19/25

H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)we reiterate our Buy ratings and price targets—$40 for COMPASS Pathways

Sumant Kulkarni

Canaccord Genuity

$15

Buy

217.80%

Upside

Reiterated

08/14/25

Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support

Judah Frommer

Morgan Stanley

$10

Buy

111.86%

Upside

Initiated

08/08/25

COMPASS Pathways (CMPS) Receives a New Rating from Morgan StanleyThe table indicates a 'Resumption' for Compass Pathways – with an Overweight rating and a new PT of $10.

Michael Okunewitch

Maxim Group

$12

Buy

154.24%

Upside

Reiterated

08/04/25

COMPASS Pathways: Leading the Psychedelic Medicine Revolution with Promising Psilocybin Trials and Strong Industry Positioning

Ritu Baral

TD Cowen

$23

Buy

387.29%

Upside

Reiterated

07/31/25

Positive Buy Rating for COMPASS Pathways Driven by Strategic Progress and Financial Stability

Leonid Timashev

RBC Capital

$15

Buy

217.80%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Hologic (NASDAQ: HOLX), Alnylam Pharma (NASDAQ: ALNY) and COMPASS Pathways (NASDAQ: CMPS)

Gavin Clark-Gartner

Evercore ISI

$11→$6

Hold

27.12%

Upside

Downgraded

07/11/25

COMPASS Pathways (CMPS) was downgraded to a Hold Rating at Evercore ISI

Paul Matteis

Stifel Nicolaus

$11

Buy

133.05%

Upside

Reiterated

06/30/25

Thomas Shrader

BTIG

$12→$7

Buy

48.31%

Upside

Reiterated

06/24/25

Compass Pathways price target lowered to $7 from $12 at BTIGCompass Pathways price target lowered to $7 from $12 at BTIG

Joshua Schimmer

Cantor Fitzgerald

$12

Buy

154.24%

Upside

Initiated

05/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

Rosa Clinessa

TR | OpenAI - 4o

―

Hold

―

Reiterated

04/24/25

AI Generated ArticleAI Generated Article

Elemer Piros

Lucid Capital

$30→$9

Buy

90.68%

Upside

Reiterated

01/27/25

Compass Pathways (CMPS) PT Lowered to $9 at Rodman RenshawRodman Renshaw analyst Elemer Piros lowered the price target on Compass Pathways (NASDAQ: CMPS) to $9.00 (from $30.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$45→$40

Buy

747.46%

Upside

Reiterated

08/19/25

H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)we reiterate our Buy ratings and price targets—$40 for COMPASS Pathways

Sumant Kulkarni

Canaccord Genuity

$15

Buy

217.80%

Upside

Reiterated

08/14/25

Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support

Judah Frommer

Morgan Stanley

$10

Buy

111.86%

Upside

Initiated

08/08/25

COMPASS Pathways (CMPS) Receives a New Rating from Morgan StanleyThe table indicates a 'Resumption' for Compass Pathways – with an Overweight rating and a new PT of $10.

Michael Okunewitch

Maxim Group

$12

Buy

154.24%

Upside

Reiterated

08/04/25

COMPASS Pathways: Leading the Psychedelic Medicine Revolution with Promising Psilocybin Trials and Strong Industry Positioning

Ritu Baral

TD Cowen

$23

Buy

387.29%

Upside

Reiterated

07/31/25

Positive Buy Rating for COMPASS Pathways Driven by Strategic Progress and Financial Stability

Leonid Timashev

RBC Capital

$15

Buy

217.80%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Hologic (NASDAQ: HOLX), Alnylam Pharma (NASDAQ: ALNY) and COMPASS Pathways (NASDAQ: CMPS)

Gavin Clark-Gartner

Evercore ISI

$11→$6

Hold

27.12%

Upside

Downgraded

07/11/25

COMPASS Pathways (CMPS) was downgraded to a Hold Rating at Evercore ISI

Paul Matteis

Stifel Nicolaus

$11

Buy

133.05%

Upside

Reiterated

06/30/25

Thomas Shrader

BTIG

$12→$7

Buy

48.31%

Upside

Reiterated

06/24/25

Compass Pathways price target lowered to $7 from $12 at BTIGCompass Pathways price target lowered to $7 from $12 at BTIG

Joshua Schimmer

Cantor Fitzgerald

$12

Buy

154.24%

Upside

Initiated

05/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

Rosa Clinessa

TR | OpenAI - 4o

―

Hold

―

Reiterated

04/24/25

AI Generated ArticleAI Generated Article

Elemer Piros

Lucid Capital

$30→$9

Buy

90.68%

Upside

Reiterated

01/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

1 Month

xxx

Success Rate

11/23 ratings generated profit

Average Return

+3.23%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.83% of your transactions generating a profit, with an average return of +3.23% per trade.

3 Months

xxx

Success Rate

12/23 ratings generated profit

Average Return

+0.15%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +0.15% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

6/23 ratings generated profit

Average Return

-15.91%

reiterated a buy rating 11 days ago

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -15.91% per trade.

2 Years

xxx

Success Rate

3/12 ratings generated profit

Average Return

-23.63%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -23.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CMPS has received 17 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CMPS average Analyst price target in the past 3 months is 15.44.

Each month's total comprises the sum of three months' worth of ratings.

CMPS Financial Forecast

CMPS Earnings Forecast

Next quarter’s earnings estimate for CMPS is -$0.40 with a range of -$0.50 to -$0.22. The previous quarter’s EPS was -$0.41. CMPS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year CMPS has Outperformed its overall industry.

No data currently available

CMPS Sales Forecast

Next quarter’s sales forecast for CMPS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.24% of the time in the same period. In the last calendar year CMPS has Preformed in-line its overall industry.

CMPS Stock Forecast FAQ

What is CMPS’s average 12-month price target, according to analysts?

Based on analyst ratings, COMPASS Pathways’s 12-month average price target is 15.44.

What is CMPS’s upside potential, based on the analysts’ average price target?

COMPASS Pathways has 227.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CMPS a Buy, Sell or Hold?

COMPASS Pathways has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is COMPASS Pathways’s price target?

The average price target for COMPASS Pathways is 15.44. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $6.00. The average price target represents 227.12% Increase from the current price of $4.72.

What do analysts say about COMPASS Pathways?

COMPASS Pathways’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of CMPS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

COMPASS Pathways (CMPS) Stock Forecast & Price Target

CMPS Analyst Ratings

CMPS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering COMPASS Pathways

CMPS Analyst Recommendation Trends

CMPS Financial Forecast

CMPS Earnings Forecast

CMPS Sales Forecast

CMPS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts